AU3011299A - Combination therapy for the treatment of benign prostatic hyperplasia - Google Patents

Combination therapy for the treatment of benign prostatic hyperplasia

Info

Publication number
AU3011299A
AU3011299A AU30112/99A AU3011299A AU3011299A AU 3011299 A AU3011299 A AU 3011299A AU 30112/99 A AU30112/99 A AU 30112/99A AU 3011299 A AU3011299 A AU 3011299A AU 3011299 A AU3011299 A AU 3011299A
Authority
AU
Australia
Prior art keywords
treatment
combination therapy
benign prostatic
prostatic hyperplasia
hyperplasia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU30112/99A
Inventor
Theodore P. Broten
Steven A. Nichtberger
Peter K. S Siegl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9810895.4A external-priority patent/GB9810895D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU3011299A publication Critical patent/AU3011299A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
AU30112/99A 1998-03-23 1999-03-19 Combination therapy for the treatment of benign prostatic hyperplasia Abandoned AU3011299A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7904198P 1998-03-23 1998-03-23
US60079041 1998-03-23
GB9810895 1998-05-20
GBGB9810895.4A GB9810895D0 (en) 1998-05-20 1998-05-20 Combination therapy for the treatment of benign prostatic hyperplasia
PCT/US1999/006014 WO1999048530A1 (en) 1998-03-23 1999-03-19 Combination therapy for the treatment of benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
AU3011299A true AU3011299A (en) 1999-10-18

Family

ID=26313720

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30112/99A Abandoned AU3011299A (en) 1998-03-23 1999-03-19 Combination therapy for the treatment of benign prostatic hyperplasia

Country Status (2)

Country Link
AU (1) AU3011299A (en)
WO (1) WO1999048530A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3200070B2 (en) 1994-11-16 2001-08-20 シナプティック・ファーマスーティカル・コーポレーション Dihydropyrimidines and uses thereof
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
WO2000027816A1 (en) * 1998-11-10 2000-05-18 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
US6228870B1 (en) 1998-11-10 2001-05-08 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
WO2000027817A1 (en) * 1998-11-10 2000-05-18 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
US6319932B1 (en) 1998-11-10 2001-11-20 Merck & Co., Inc. Oxazolidinones useful as alpha 1A adrenoceptor antagonists
AU1345900A (en) * 1998-11-10 2000-05-29 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
GB2344821A (en) * 1998-12-17 2000-06-21 Merck & Co Inc Crystalline pharmaceutically acceptable salt of an oxazolidinone derivative
AU2386800A (en) * 1998-12-23 2000-07-12 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6680323B2 (en) 1998-12-23 2004-01-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6274585B1 (en) * 1998-12-23 2001-08-14 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
NL1015313C2 (en) 2000-05-26 2001-11-27 Dsm Nv Process for the preparation of enantiomerically enriched esters and alcohols.
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
JP2001288115A (en) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd Remedy for lower urinary tract symptom
ES2237515T3 (en) * 2001-09-14 2005-08-01 Schwarz Pharma Ag TRANSDERMAL ADMINISTRATION DEVICE FOR THE TREATMENT OF URINARY TRACT DISORDERS.
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
CA2557758C (en) * 2004-03-05 2013-09-10 Kissei Pharmaceutical Co., Ltd. Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE189217T1 (en) * 1993-03-19 2000-02-15 Merck & Co Inc PHENOXYPHENYLACETIC ACID DERIVATIVES
JP2847969B2 (en) * 1993-08-18 1999-01-20 萬有製薬株式会社 Heteroaromatic fused cyclopentene derivatives with endothelin antagonist activity
CA2195758A1 (en) * 1994-08-08 1996-02-22 Scott W. Bagley Phenoxyphenylacetic acid derivatives
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
JP3200070B2 (en) * 1994-11-16 2001-08-20 シナプティック・ファーマスーティカル・コーポレーション Dihydropyrimidines and uses thereof
EA000061B1 (en) * 1995-01-27 1998-04-30 Рон-Пуленк Рорер Лимитед Substituted phenyl compounds as endothelin antagonists
US5597823A (en) * 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists

Also Published As

Publication number Publication date
WO1999048530A1 (en) 1999-09-30

Similar Documents

Publication Publication Date Title
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
AU2212299A (en) Compositions and methods for the treatment of tumor
SI0968208T1 (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
AU6393896A (en) Method for treating benign prostatic hyperplasia with thermal therapy
IL189132A0 (en) Pharmaceutical compositions for the treatment of prostate hypertrophy and prostate cancer
AU3891299A (en) Combination therapy for treatment of depression
AU1316000A (en) Compositions and methods for treating benign prostatic hyperplasia using tocotrienols
AU2235395A (en) Biological markers of benign prostate hyperplasia
EP0855910A4 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
AU6062900A (en) Substituted indole compounds and their use for the treatment of cancer
ZA983968B (en) Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia.
AU7105498A (en) Combination therapy for the prevention and treatment of osteoporosis
HUP0101947A3 (en) Combination for the treatment of tumors
ZA982819B (en) Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
HK1030776A1 (en) Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
AU2001285156A1 (en) Combination therapy for the treatment of migraine
AU9128998A (en) Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
AU1940800A (en) Combination therapy for the treatment of sepsis
GB9810895D0 (en) Combination therapy for the treatment of benign prostatic hyperplasia
AU2390700A (en) Polypeptidic compositions and methods for the treatment of tumors
AU1036701A (en) Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia
ZA991319B (en) Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia.
EP0748627A3 (en) Melatonin agonists for use in the treatment of benign prostatic hyperplasia
AU4118900A (en) Methods for the gene therapy of benign prostatic hyperplasia and medical agents therefore

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase